SCHEMBL16291785

SCHEMBL16291785

Fc1ccc(/C=C\c2nc3ccccc3n2Cc2ccccc2Cl)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 9/20 0.64
▸ ALDH1A1 P00352 8/20 0.64
▸ MAPT P10636 8/20 0.64
▸ HPGD P15428 7/20 0.64
▸ KDM4E B2RXH2 7/20 0.64
▸ GAA P10253 6/20 0.64
▸ LMNA P02545 4/20 0.64
▸ HTT P42858 4/20 0.64
▸ NPSR1 Q6W5P4 3/20 0.64
▸ POLB P06746 1/20 0.64
▸ TP53 P04637 5/20 0.62
▸ RAB9A P51151 7/20 0.60
▸ L3MBTL1 Q9Y468 5/20 0.60
▸ NPC1 O15118 5/20 0.59
▸ NFKB1 P19838 3/20 0.59
▸ NFKB2 Q00653 3/20 0.59
▸ RELA Q04206 3/20 0.59
▸ RCE1 Q9Y256 1/20 0.59
▸ TDP1 Q9NUW8 3/20 0.56
▸ TNF P01375 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22822617 0.90 SMN1; SMN2 (0.69) SMN1; SMN2ALDH1A1MAPTHPGDKDM4E
SCHEMBL16291782 0.81 MAPT (0.53) SMN1; SMN2ALDH1A1MAPTHPGDKDM4E
SCHEMBL16291783 0.81 MAPT (0.53) SMN1; SMN2ALDH1A1MAPTHPGDKDM4E
SCHEMBL20767461 0.81 SMN1; SMN2 (0.65) SMN1; SMN2ALDH1A1MAPTHPGDKDM4E
SCHEMBL20767462 0.81 SMN1; SMN2 (0.65) SMN1; SMN2ALDH1A1MAPTHPGDKDM4E
SCHEMBL22822640 0.80 SMN1; SMN2 (0.68) SMN1; SMN2ALDH1A1MAPTHPGDKDM4E
SCHEMBL24120015 0.79 SMN1; SMN2 (0.60) SMN1; SMN2ALDH1A1MAPTHPGDKDM4E
SCHEMBL22822622 0.76 SMN1; SMN2 (0.69) SMN1; SMN2ALDH1A1MAPTHPGDKDM4E
SCHEMBL22822870 0.76 SMN1; SMN2 (0.73) SMN1; SMN2ALDH1A1MAPTHPGDKDM4E
SCHEMBL22822636 0.75 ALDH1A1 (0.76) SMN1; SMN2ALDH1A1MAPTHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10633369-B2 Method of inhibiting DYRK1B 4 SC AG (DE) 2020-04-28 — — US disclosed
US-20180201606-A1 METHOD OF INHIBITING DYRK1B 4 SC AG (DE) 2018-07-19 — — US disclosed
US-9951050-B2 Method of inhibiting DYRK1B 4 SC AG (DE) 2018-04-24 — — US disclosed
US-20140371251-A1 METHOD OF INHIBITING DYRK1B 4SC DISCOVERY GMBH (DE) 2014-12-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10633369-B2 Method of inhibiting DYRK1B SMO, GLI1, GRK2 SMN1; SMN2 4360/4885ALDH1A1 3401/4885MAPT 4239/4885
US-20180201606-A1 METHOD OF INHIBITING DYRK1B SMO, GLI1, GRK2 SMN1; SMN2 4360/4885ALDH1A1 3401/4885MAPT 4239/4885
US-20140371251-A1 METHOD OF INHIBITING DYRK1B SMO, GLI1, GRK2 SMN1; SMN2 4360/4885ALDH1A1 3401/4885MAPT 4239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback